Login
Contact

Explore

Explore

About
  • People and Partners
  • TRI Building
  • Reconciliation Action Plan
  • Strategic Plan
  • TRI Foundation
  • Careers
Research
  • Collaborate
  • Discovery
  • Translate
  • Engage
  • Research Areas
Clinical
  • Translational Trials
  • Clinical Research Facility
  • TRI at Children’s
Industry
  • TRI Incubator
  • The Precinct
  • Residents
Manufacture
  • New cGMP Facility
Facilities
  • Cleanroom
  • Flow Cytometry
  • Histology
  • Microscopy
  • Proteomics
  • Preclinical Imaging
  • Biological Research
  • Gnotobiotics
  • Human Immune Model
Get Involved
  • Health Consumers
  • SPARQ-ed
Resources
  • News
  • Events
  • Case Studies
  • Grants and Funding
  • Education and Training
+61 7 3443 7000info@tri.edu.au37 Kent Street, Woolloongabba QLD 4102 Australia

Acknowledgement of Country

TRI acknowledges the traditional custodians of the land we are on today, the Turrbal and Jagera people and we recognise their continuing connection to land, waters and community. We pay deep respect to them and their cultures; and to Elders past, present and emerging.

© Translational Research Institute Pty Ltd atf the Translational Research Institute Trust|ABN: 58 155 991 662
Privacy policy|Terms of Use|Contact Us
TRI · Gut and lung focus to immune response research

Case Studies

Gut and lung focus to immune response research

A TRI-based research team from The University of Queensland’s Frazer Institute is focusing on the gut and lungs, as part wider work into understanding immune responses and how they protect against infections, viruses, parasites and even cancer.

Professor Gabrielle Belz leads research in understanding how the linings of the gut and lungs form a barrier, protecting the body by triggering immune responses or repairing damage.

Key points
  • Professor Gabrielle Belz from The University of Queensland’s Frazer Institute is leading a team based at TRI to better understand epithelial cells and their role in immune responses.
  • The cells are found in abundance in the linings of the gut and lungs, where they encounter food and airborne pathogens.
  • Professor Belz has support from a prestigious Australian Research Council (ARC) Laureate Fellowship, worth $3.4 million.
  • Team goals are to uncover new knowledge to discover therapies that boost the immune system to guard against infection from bacteria and viruses – particularly streptococcus bacteria and influenza and herpes viruses, as well as fight cancer and autoimmune diseases.
The role of epithelial cells

Understanding how the body deals with pathogens such as infections, viruses and parasites requires study of important immune cells and systems, which are found in many parts of the body.

Among the most important are epithelial cells, considered to be at the crossroads between the external and the internal world because they encounter food and airborne pathogens. The cells are found in abundance in the linings of the gut and lungs.

Epithelial cells cooperate with beneficial bacteria in the gut and play a key role as frontline responders, sending signals triggering specific immune responses to invading pathogens.

Understanding mechanisms triggering immunity

Professor Belz is the UQ Chair in Immunology and leads a team focussing on understanding signals that trigger immune responses against pathogen infections, such as influenza and herpes viruses.

Her research has enabled tracking of virus-specific T cells in the immune system, uncovered the role of specific T cells in triggering antiviral responses, and identified key dendritic cells involved in immune responses to viral infections.

The research ultimately aims to contribute to developing vaccines for infectious disease and better treatments for autoimmune diseases.

Her team is now using the knowledge to study key cell signals, immune cell development, and mechanisms triggering immune responses in the nose, mouth, lungs and stomach – both to overwhelm infections and build long-lived protective immune memory.

“There are still some really big gaps in how we understand the body defending against pathogen infections,” Professor Belz says.

“We are determining how different types of immune cells develop, and what factors influence their decision to become one type of immune cell or another.

“Understanding how the body deals with pathogens will give clues about how to enhance protective immunity. Our goal is to discover new therapies that boost our immune system to protect against infection.”

Prestigious fellowship to advance cell function understanding

Professor Belz has been awarded a prestigious Australian Research Council (ARC) Laureate Fellowship, with more than $3.4 million to now also study the way cells function at the epithelial barrier.

Her work is expected to advance drug and vaccine development and delivery, with benefits to the wider Australian society, the biomedical technology sector and the economy.

Epithelial cells form the protective layer of the body. There are several different types of epithelial cells, some of which are specialised to interact with immune cells, and they are the first cells to encounter infectious organisms.

More immune cells are found in the tissue layers beneath the protective barriers (skin and mucosa lining the gut and lungs) than any other parts of the body.

Despite this, how epithelial cells communicate with immune cells to establish the critical immune cascade that protects the body is not well understood. However, this knowledge is essential to uncover the rules for how to better deliver vaccines and drugs to the body, particularly targeting mucosal surfaces.

The new knowledge will enable development of unique biopharmaceuticals, help build new sovereign capabilities, bolster workforce capabilities and reduce the burden of disease.

 

Publications

  1. Huang Q, H J Cao W, Curio S, Yu H, Denman R, Chen E, Schreuder J, Dight J, Chaudhry M, Jacquelot N, Wimmer VC, Seillet C, Möröy T, Belz GT. GFI1B specifies developmental potential of innate lymphoid cell progenitors in the lungs. Sci Immunol. 2024 31;9(95):eadj2654. doi: 10.1126/sciimmunol.adj2654. PMID: 38820141.
  2. Jacquelot, N., Seillet, C., Wang, M., Pizzolla, A., Liao, Y., Hediyeh-Zadeh, S., Grisaru-Tal, S., Louis, C., Huang, Q., Schreuder, J., Souza-Fonseca-Guimaraes, F., de Graaf, C.A., Thia, K., Macdonald, S., Camilleri, M., Luong, K., Zhang, S., Chopin, M., Molden-Hauer, T., Nutt. S.L., Umansky, V., Ciric, B., Groom, J.R., Foster, P.S., Hansbro, P.M., McKenzie, A.N.J., Gray, D.H.D., Behren, A., Cebon, J., Vivier, E., Wicks, I.P., Trapani, J..A, Munitz, A., Davis, M.J., Shi, W., Neeson, P.J., BELZ, G.T. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat. Immunol. 2021, 22:851-864. doi: 10.1038/s41590-021-00943-z.
  3. Seillet C, Luong K, Tellier J, Jacquelot N, Shen RD, Hickey P, Wimmer VC, Whitehead L, Rogers K, Smyth GK, Garnham AL, Ritchie ME, BELZ GT. 2020. Vasoactive intestinal peptide confers anticipatory mucosal immunity by regulating ILC3 activity. Nature Immunology, 21:168-177.

Stay informed with the latest in medical research. Subscribe to TRI NEWS.

Stay informed with the latest in medical research. Subscribe to TRI NEWS.